Compare KRP & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | WGS |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2017 | N/A |
| Metric | KRP | WGS |
|---|---|---|
| Price | $15.23 | $47.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $17.33 | ★ $120.71 |
| AVG Volume (30 Days) | 949.4K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $333,830,000.00 | N/A |
| Revenue This Year | $6.88 | $29.98 |
| Revenue Next Year | N/A | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $11.31 | $32.21 |
| 52 Week High | $15.65 | $170.87 |
| Indicator | KRP | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 44.37 |
| Support Level | $14.10 | $32.21 |
| Resistance Level | $15.65 | $96.34 |
| Average True Range (ATR) | 0.32 | 3.76 |
| MACD | -0.01 | 1.16 |
| Stochastic Oscillator | 71.84 | 87.40 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.